Delving into the Latest Updates on Ticagrelor with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ticagrelor (JAN/USAN/INN), Ticagrelor-D578, AR-C-126532

+ [14]

Target

P2Y12 receptor

Action

antagonists

Mechanism

P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases

Active Indication

Acute Ischemic StrokeIschemic Attack, TransientCoronary Artery Disease+ [7]

Inactive Indication

Acute Chest SyndromeAcute myocardial infarctionAnalgesia+ [17]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

Libbs Farmacêutica Ltda.AstraZeneca Pharmaceuticals LPAstraZeneca AB

+ [6]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (03 Dec 2010),

Acute Coronary SyndromeAtherosclerosis

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC23H28F2N6O4S

InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N

CAS Registry274693-27-5

This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor monotherapy to standard 6-month DAPT with aspirin and clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The primary endpoint is a composite of cardiovascular death, all-cause death, myocardial infarction, disabling stroke, target lesion revascularization (TLR), and major bleeding. The study aims to evaluate whether the short DAPT strategy reduces ischemic events while maintaining bleeding safety.

Start Date01 Dec 2025

Sponsor / Collaborator

University of Messina

ChiCTR2500112634

/ Not yet recruitingNot ApplicableIIT

Low-Dose Versus Standard-Dose Ticagrelor for Secondary Stroke Prevention in Minor Stroke or High-Risk TIA Patients with CYP2C19 Loss-of-Function Alleles (LIGHT): A Randomized Non-Inferiority Trial

Start Date14 Nov 2025

Sponsor / Collaborator

Yichang Central People's Hospital

100 Clinical Results associated with Ticagrelor

Login to view more data

100 Translational Medicine associated with Ticagrelor

Login to view more data

100 Patents (Medical) associated with Ticagrelor

Login to view more data

4,553

Literatures (Medical) associated with Ticagrelor

01 Feb 2026·NEUROPHARMACOLOGY

Ticagrelor as a dual RAS modulator and mitochondrial stabilizer: A multifaceted neurotherapeutic strategy in Huntington's disease

Article

Author: Abou El-Ezz, Doaa ; Sayed, Rabab H ; El-Brairy, Amany ; Abdallah, Dalaal M ; El-Abhar, Hanan S ; Mohamed, Ola E

The pathobiology of Huntington's disease (HD) is far from complete. Although limited, patients have been reported to exhibit altered platelet function, enhanced ENT1, and changes in renin-angiotensin system (RAS), all of which may impact cognitive function. Ticagrelor has demonstrated neuroprotective effects in stroke and parkinsonism models through mechanisms that extend beyond its therapeutic benefits as a P2Y12 receptor antagonist and ENT1 inhibitor. In this study, we investigated the potential efficiency Ticagrelor post-treatment on motor defects in a 3-nitropropionic acid (3-NP)-induced HD-like model. Symptomatic HD rats were daily treated for a week with Ticagrelor, the MAS receptor (MAS-R) antagonist A-779, or Ticagrelor + A-779. Ticagrelor amended body weight loss, motor function in open field and rotarod tests, and striatal histopathological alterations induced by 3-NP. On the striatal molecular level, Ticagrelor downregulated prorenin receptor mRNA expression but upregulated that of the MAS-R. Additionally, it decreased striatal contents of prorenin/renin and angiotensin II (Ang II), while increasing those of angiotensin-converting enzyme 2 and Ang-(1-7). Ticagrelor also hindered the phosphorylation/activation of the inositol trisphosphate receptor (IP3R), dynamin-related protein-1 (DRP-1), and PTEN-induced putative kinase 1 protein (PINK1) expressions. Additionally, it boosted the voltage-dependent anion channel-1 (VDAC-1) and Mitofusin-2 (Mnf-2) striatal contents. A-779 partially reverted Ticagrelor impact on all amendments except for prorenin receptor and p-IP3R. However, prorenin/renin correlated markedly with IP3R, DRP-1, and PINK1, but inversely with VDAC-1 and Mfn-2. In conclusion, Ticagrelor demonstrates promising neurotherapeutic effects in HD partially via the activation of MAS-R, inhibition of prorenin/renin/prorenin receptor, and improvement of mitochondrial homeostasis.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Ticagrelor/Prasugrel or clopidogrel in acute coronary syndrome and advanced chronic kidney disease: Is more potency worth the risk?

Author: Pan, Deng ; Guo, Xinru

01 Jan 2026·JOURNAL OF CLINICAL NEUROSCIENCE

Dual antiplatelet therapy guided by CYP2C19 polymorphism after intracranial or extracranial stenting: A single-center retrospective cohort study

Article

Author: Mengchi, Pu ; Qingyu, Fan ; Hong, Fan ; Ye, Li ; Guilian, Zhang ; Fangcun, Li

OBJECTIVE:

To evaluate the efficacy and safety of three distinct dual antiplatelet therapy (DAPT) strategies following intracranial and extracranial neurovascular stenting. under the guidance of CYP2C19 genotyping.

METHODS:

In this single-center, retrospective cohort study, consecutive patients who underwent elective neurovascular stenting in the Department of Neurology, Second Affiliated Hospital of Xi'an Jiaotong University, from January 2020 to December 2024 and completed 90-day follow-up were retrospectively enrolled. All patients received DAPT for 90 days (starting 3 days before the procedure). In Part I, patients were stratified into a genotype-guided group (n = 938) and a conventional group (n = 218) according to whether CYP2C19 genotyping was performed. In the genotype-guided group, CYP2C19 rapid metabolizers received clopidogrel (75 mg qd) plus aspirin (100 mg qd), whereas intermediate or poor metabolizers received ticagrelor (90 mg bid) or cilostazol (100 mg bid) plus aspirin (100 mg qd). The conventional group received clopidogrel plus aspirin. The primary efficacy outcome was new ischemic stroke within 90 days. In Part II, genotype-guided patients were further classified into clopidogrel, ticagrelor, and cilostazol subgroups, all combined with aspirin. The primary efficacy endpoint remained 90-day ischemic stroke; the primary safety endpoint was moderate-to-severe bleeding within 90 days.

RESULTS:

Of 1,270 included patients, 1,156 completed 90-day follow-up. Baseline characteristics were balanced between the genotype-guided and conventional groups (all P > 0.05). The 90-day ischemic stroke rate was significantly lower with genotype-guided therapy (3.73 % vs 6.88 %; P = 0.039). Within the genotype-guided cohort, baseline variables were balanced across clopidogrel (n = 386), ticagrelor (n = 330), and cilostazol (n = 222) subgroups (all P > 0.05). A significant difference in ischemic stroke rates was observed among the three DAPT regimens (P = 0.034), forming an efficacy gradient: clopidogrel in rapid metabolizers (2.33 %), ticagrelor (3.63 %), and cilostazol (5.96 %). Post-hoc analysis showed a higher risk with cilostazol versus clopidogrel (relative risk 2.55; P = 0.0097). The incidence of moderate-to-severe bleeding was similar low across all groups (clopidogrel 0.42 %, ticagrelor 0.61 %, cilostazol 0.33 %; P > 0.05), However, ticagrelor was associated with a significantly higher rate of any bleeding event (7.27 %) compared to both clopidogrel (2.33 %) and cilostazol (0.99 %). Multivariable analysis established the DAPT regimen as an independent predictor of ischemic stroke.

CONCLUSIONS:

CYP2C19 genotype- DAPT significantly reduces the risk of ischemic stroke within 90 days after intracranial or extracranial stenting. For CYP2C19 loss-of-function allele carriers, ticagrelor plus aspirin offers a more effective antithrombotic effect compared to cilostazol plus aspirin, albeit with a higher risk of manageable bleeding events. An individualized strategy is recommended: ticagrelor should be prioritized for ischemic prevention in most patients, while cilostazol represents a safer alternative for those at very high bleeding risk.

123

News (Medical) associated with Ticagrelor

24 Nov 2025

·www.biopharmadive.com

Bayer’s experimental blood-thinner notches trial win in stroke prevention

Dive Brief:Bayers experimental blood thinner asundexianmet its main goal in a closely watched Phase 3 stroke prevention trial, reducing the recurrence of a stroke in people who took the therapy along with standard treatments. The trial compared treatment with a combination of asundexian and an antiplatelet therapy against a placebo and the same antiplatelet treatment.The German-based company didnt release detailed data, stating that researchers will disclose them at an upcoming medical meeting while company executives discuss them with regulators ahead of possible approval applications.Results of the trial lifted optimism for asundexian'sdrug class, called Factor XIa inhibitors, following a series of clinical setbacks. Most recently, a rival drug missed its main goal in a trial of people whod had a recent heart attack.Dive Insight:The spotlight has been on Factor XIa inhibitors as the next big innovation in cardiovascular medicine, with drugmakers and researchers hoping they will prove safer and more effective than aging franchises like Bristol Myers Squibbs Eliquis. These drugs, which include asundexian,Bristol Myers and Johnson & Johnsons milvexian and Novartis abelacimab, block a protein involved in forming blood clots but is believed to be less essential in stopping bleeding.The balancing act in preventing stroke or any acute cardiovascular episode due to blood vessel blockages is in suppressing clotting without raising the risk that people will have uncontrolled bleeding incidents. In people who have irregular heartbeats, Eliquis is able to do just that better than an older drug called warfarin or aspirin.In treating people whove already had one stroke that wasnt caused by an irregular heartbeat, in a setting called secondary prevention, doctors use one or two drugs to thin the blood, known as antiplatelet medications. The drugs used include aspirin, clopidogrel, AstraZenecas Brilinta and Eli Lillys Effient.In the trial called Oceanic Stroke, Bayer aimed to measure whether adding asundexianto the mix would help, testing it against a placebo in over 12,000 people. The company said the experimental drug reduced the risk of ischemic stroke compared to placebo and added that its addition didnt increase the risk of major bleeding episodes.Bayers German-listed shares rose more than 12% following the news, changing hands at about 31 euros apiece. Two years ago, Bayer terminated a head-to-head trial of asundexianagainst Eliquis in people with irregular heartbeats, an early Phase 3 readout that cast some doubt over the promise of Factor XIa inhibitors.Milvexiansfailure in acute coronary syndrome earlier this month didnt boost optimism, but the asundexianresults may reverse some of the doubt.After a string of class setbacks, this is a needed win, wrote Cantor Fitzgerald analyst Carter Gould, who covers Bristol Myers, in a note to clients.Bristol Myers and J&J are expecting milvexiansPhase 3 trials in people with irregular heartbeats, as well as secondary stroke prevention, in the fourth quarter of 2026. Bristol Myers shares rose 5% in morning trading. '

Phase 3

14 Nov 2025

·pharma.economictimes.indiatimes.com

Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

London: Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found. All 1,800 study participants had Type 1 or Type 2 diabetes , and all had undergone minimally invasive interventions to clear a clogged coronary artery and prop it open using a drug-coated stent to help reduce the risk of reclogging. Afterward, they received aspirin plus either AstraZeneca's Brilinta (ticagrelor) or Effient (prasugrel), sold by Eli Lilly and Daiichi Sankyo, from a class of drugs known as P2Y12 inhibitors that are prescribed to prevent the formation of blood clots. The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the prasugrel group, researchers reported at the recent American Heart Association Scientific Sessions in New Orleans. Patterns were similar when rates of non-fatal heart attack, major bleeding, and death were analyzed separately. "For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor," study leader Dr. Sripal Bangalore of the NYU Grossman School of Medicine said in a statement. "We were surprised by the results because we hypothesized that ticagrelor should be as good or perhaps even better than prasugrel," he said. "It's important to choose the right medicine, and at least from our data, we cannot say that ticagrelor and prasugrel are interchangeable." GENERAL ANESTHESIA APPEARS SAFE FOR C-SECTIONS General anesthesia is a reasonable option for women giving birth via cesarean section, especially when spinal or epidural nerve blocks are ineffective, a new analysis shows. Up to one in six women who receive regional anesthesia during a cesarean section may feel pain, and for some, the pain can be excruciating, but general anesthesia has long been avoided due to concerns about its effects on the baby, researchers noted in a report of their study in Anesthesiology. They analyzed 30 years of data from dozens of randomized trials involving nearly 3,500 infants born via cesarean section. Roughly half of the surgeries were done with general anesthesia. While babies born under spinal or epidural anesthesia had slightly higher Apgar scores - a measure of newborn health - than those born under general anesthesia, the differences were small and not likely to be clinically meaningful, the researchers found. They also found that babies born under general anesthesia were slightly more likely to need breathing support immediately after birth, but there was no increase in neonatal ICU admissions. The research does not suggest that general anesthesia should replace localized techniques, but it can be a reasonable option in certain cases, the authors said. "Since regional anesthesia is so widely used, it's common for patients to feel that a spinal or epidural block is the only safe option for cesarean section," study leader Dr. Mark Neuman of the Perelman School of Medicine at the University of Pennsylvania said in a statement. "But as our study shows, anesthesia type during pregnancy does not need to be one-size-fits-all." (To receive the full newsletter in your inbox for free sign up here) (Reporting by Nancy Lapid; Editing by Bill Berkrot)

AHAClinical Result

14 Nov 2025

·pharma.economictimes.indiatimes.com

Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

London: Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found. All 1,800 study participants had Type 1 or Type 2 diabetes , and all had undergone minimally invasive interventions to clear a clogged coronary artery and prop it open using a drug-coated stent to help reduce the risk of reclogging. Afterward, they received aspirin plus either AstraZeneca's Brilinta (ticagrelor) or Effient (prasugrel), sold by Eli Lilly and Daiichi Sankyo, from a class of drugs known as P2Y12 inhibitors that are prescribed to prevent the formation of blood clots. The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the prasugrel group, researchers reported at the recent American Heart Association Scientific Sessions in New Orleans. Patterns were similar when rates of non-fatal heart attack, major bleeding, and death were analyzed separately. "For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor," study leader Dr. Sripal Bangalore of the NYU Grossman School of Medicine said in a statement. "We were surprised by the results because we hypothesized that ticagrelor should be as good or perhaps even better than prasugrel," he said. "It's important to choose the right medicine, and at least from our data, we cannot say that ticagrelor and prasugrel are interchangeable." GENERAL ANESTHESIA APPEARS SAFE FOR C-SECTIONS General anesthesia is a reasonable option for women giving birth via cesarean section, especially when spinal or epidural nerve blocks are ineffective, a new analysis shows. Up to one in six women who receive regional anesthesia during a cesarean section may feel pain, and for some, the pain can be excruciating, but general anesthesia has long been avoided due to concerns about its effects on the baby, researchers noted in a report of their study in Anesthesiology. They analyzed 30 years of data from dozens of randomized trials involving nearly 3,500 infants born via cesarean section. Roughly half of the surgeries were done with general anesthesia. While babies born under spinal or epidural anesthesia had slightly higher Apgar scores - a measure of newborn health - than those born under general anesthesia, the differences were small and not likely to be clinically meaningful, the researchers found. They also found that babies born under general anesthesia were slightly more likely to need breathing support immediately after birth, but there was no increase in neonatal ICU admissions. The research does not suggest that general anesthesia should replace localized techniques, but it can be a reasonable option in certain cases, the authors said. "Since regional anesthesia is so widely used, it's common for patients to feel that a spinal or epidural block is the only safe option for cesarean section," study leader Dr. Mark Neuman of the Perelman School of Medicine at the University of Pennsylvania said in a statement. "But as our study shows, anesthesia type during pregnancy does not need to be one-size-fits-all." (To receive the full newsletter in your inbox for free sign up here) (Reporting by Nancy Lapid; Editing by Bill Berkrot)

AHAClinical Result

100 Deals associated with Ticagrelor

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09017	Ticagrelor	B01AC24	DB08816

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Ischemic Stroke	United States	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Ischemic Attack, Transient	United States	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Coronary Artery Disease	United States	AstraZeneca Pharmaceuticals LP	28 May 2020
Myocardial Infarction	Japan	AstraZeneca KK	28 Sep 2016
Angina, Unstable	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
Non-St Elevated Myocardial Infarction	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
ST Elevation Myocardial Infarction	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
Acute Coronary Syndrome	European Union	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Iceland	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Liechtenstein	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Norway	AstraZeneca AB	03 Dec 2010
Atherosclerosis	European Union	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Iceland	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Liechtenstein	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Norway	AstraZeneca AB	03 Dec 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Chest Syndrome	Phase 3	-	AstraZeneca PLC	30 Jun 2020
Diabetes Mellitus	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Microvascular Disease	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Anemia, Sickle Cell	Phase 3	United States	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Belgium	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Brazil	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Egypt	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Ghana	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Greece	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	India	AstraZeneca PLC	26 Sep 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04078737 (CHANCE-2, Pubmed \| J Am Heart Assoc)	Phase 3	Ischemic Attack, Transient \| Ischemic stroke	5,651	Aspirin-Ticagrelor	ozdrtylpse(cnyxifztql) = ofoovphdfo etdswuwbkk (qszxfjgyau ) View more	Positive	18 Dec 2025
				Clopidogrel-Aspirin	ozdrtylpse(cnyxifztql) = pgjgupzbfr etdswuwbkk (qszxfjgyau ) View more
NCT03560310 (TACSI, Pubmed \| N Engl J Med)	Phase 3	Acute Coronary Syndrome	2,201	Ticagrelor plus aspirin	dravjkzgyc(welbqtlcsd) = ygdjxqtqlf zvwgtoymzo (ogmuhfayye ) View more	Negative	11 Dec 2025
				Aspirin alone	dravjkzgyc(welbqtlcsd) = gixfknqqwi zvwgtoymzo (ogmuhfayye ) View more
NCT06318481 (TADCLOT, Pubmed \| J Am Coll Cardiol)	Phase 4	ST Elevation Myocardial Infarction	2,201	Ticagrelor (180 mg loading dose, 90 mg BID)	yeacxskygb(bexbblekft) = zwphbiigms wluoftjcnk (qoatqemhzp ) View more	Negative	01 Dec 2025
				Clopidogrel (600 mg loading dose, 75 mg BID)	yeacxskygb(bexbblekft) = vsgzbgnzfp wluoftjcnk (qoatqemhzp ) View more
NCT03465644 (TAILORED-CHIP, Pubmed \| Eur Heart J)	Phase 4	-	2,018	Tailored antiplatelet strategy with early escalation and late de-escalation	eehfrkmyne(lchczvwzfm) = bfisjpetjx pswyuvrivw (cwnxkbrxxu ) View more	Negative	31 Aug 2025
				Dual antiplatelet therapy	eehfrkmyne(lchczvwzfm) = yrjqnheihb pswyuvrivw (cwnxkbrxxu ) View more
NCT04483583 (SWAP-AC-2, CTgov)	Phase 4	Coronary Artery Disease	81	Clopidogrel (ABCD-GENE >10 - Clopidogrel)	gnmxohdgbq(azlsadrfds) = tlzubhienq uejdduebqj (gwegoxigvt, lvvpzgjcur - zzkakvpupo) View more	-	31 Jul 2025
				Ticagrelor 60mg (ABCD-GENE >10 - Ticagrelor)	gnmxohdgbq(azlsadrfds) = spiahomlgi uejdduebqj (gwegoxigvt, tscsjllkfy - flgrjwixvt) View more
NCT02733341 (CTgov)	Phase 4	Acute Coronary Syndrome \| Angina, Unstable \| ST Elevation Myocardial Infarction ... View more	100	Ticagrelor (Oral Ticagrelor)	dwbqnjuyyh(gnhkeuputz) = beqivyioge sbbfelarov (rbnvtukjlo, 55.1) View more	-	02 May 2025
				Cangrelor (Intravenous Cangrelor)	dwbqnjuyyh(gnhkeuputz) = zzpkechtye sbbfelarov (rbnvtukjlo, 50.6) View more
NCT04484259 (OPTIMUS-7, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease	105	Ticagrelor monotherapy (Ticagrelor)	sxthojzjnn(qsnjhduabn) = yluhsuwvjy bezxjgacje (ncmvwtrrps, xubrhlctmi - yaudtoqnkt) View more	-	30 Mar 2025
				Clopidogrel+aspirin (Aspirin Plus Clopidogrel)	sxthojzjnn(qsnjhduabn) = scpawubzyy bezxjgacje (ncmvwtrrps, epugasrcur - gqdwxnunry) View more
NCT04078737 (CHANCE-2, Pubmed \| Stroke Vasc Neurol)	Phase 3	Stroke \| Ischemic Attack, Transient \| Carotid Stenosis	5,920	Aspirin-Ticagrelor	cmxgptcqhp(tghqabjjel) = skaxzhphbu nqppvjimov (ypaivntwbb )	Positive	07 Jan 2025
				Aspirin-Clopidogrel	cmxgptcqhp(tghqabjjel) = mlhdyuivje nqppvjimov (ypaivntwbb )
NCT03606642 (SYNIVUS-DAPT, CTgov)	Phase 2	Hemorrhage \| Coronary Artery Disease \| Atherosclerosis	50	The Synergy® stent	mhoocthpic = exnqcqmrsu uwrjndltva (umjulehjtc, ryyqyemoqr - qwzdhymtuq) View more	-	27 Dec 2024
NCT05553613 (TICA-CLOP STUDY, Pubmed \| CNS Drugs)	Phase 3	Acute Ischemic Stroke	900	Ticagrelor	blnszeohvi(hnljfmndvs): HR = 0.46 (95% CI, 0.34 - 0.83), P-Value = 0.006	Positive	09 Nov 2024
				Clopidogrel